drugset / Trial / NCT04446065
Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers
Phase 2/3
Unknown
524 enrolled
MELISA Institute Genomics & Proteomics Research SpA
Universidad Austral · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this clinical trial is to determine the efficacy of Previfenon® (EGCG) to prevent COVID-19, enhance systemic immunity, and decrease the frequency and intensity of selected symptoms when used as pre-exposure chemoprophylaxis to SARS-CoV-2.
Timeline
- Start
- 2020-09-30
- Primary completion
- 2021-09-30
- Completion
- 2021-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epigallocatechin gallate | Small molecule | 250 mg | — |